Total costs were calculated for each treatment arm in each study separately.
In 10 studies, the costs were calculated based on accounting.
Unit costs were calculated as a capacity cost rate, measured as a $/min, for each resource consumed in CABG production.
Running costs were calculated in half of the clinics also.
Hospital costs were calculated using hospital department-specific Medicare cost/charge ratios.
Monthly costs were calculated and stratified by treatment group and clinical phase.
Net costs were calculated between antiplatelet therapy groups according to level of ischemic and bleeding risk.
Direct medical costs were calculated for inpatient and outpatient visits and procedures, including administration of growth factors and MC.
Total costs were calculated by summing costs for medical resources, plus costs of institutional care and study medications and administration.
DATA SOURCES: Costs were calculated from estimated rates of health services use and unit costs of resource use.
The total costs were calculated by adjusting for inflation, then converting to U.S. dollars where necessary.
